Evidence map›Paper›PMID 38179183›Full record

ArticleFrontiers in behavioral neuroscience2023

In depth behavioral phenotyping unravels complex motor disturbances in

Eveliina Pollari, Saara Tegelberg, Harry Björklund, Reetta Kälviäinen, Anna-Elina Lehesjoki, Antti Haapalinna

Open access · goldAbstract read
In one paragraph

Article in Frontiers in behavioral neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Exploring the role of apolipoprotein ε4 in progressive myoclonic epilepsy type 1.Epileptic disorders : international epilepsy journal with videotape · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Eveliina PollariR&D, Orion Pharma Corporation, Turku, Finland.
Saara TegelbergFolkhälsan Research Center and Medicum, Medical Faculty, University of Helsinki, Helsinki, Finland.
Harry BjörklundR&D, Orion Pharma Corporation, Turku, Finland.
Reetta KälviäinenEpilepsy Center, Neuro Center, Kuopio University Hospital, Kuopio, Finland.
Anna-Elina LehesjokiFolkhälsan Research Center and Medicum, Medical Faculty, University of Helsinki, Helsinki, Finland.
Antti HaapalinnaR&D, Orion Pharma Corporation, Turku, Finland.
Orion Corporation (Finland) · FIUniversity of Helsinki · FIUniversity of Eastern Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive myoclonus epilepsy type 1 (EPM1) is an autosomal recessively inherited childhood-adolescence onset neurodegenerative disease caused by mutations in the cystatin B (

Indexed as

behavioral phenotypeCatWalkcystatin Belevated plus mazeEPM1hyperactivitymyoclonusstartle response

Identifiers

PMID38179183
PMCPMC10764494
OpenAlexW4390056585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.